Deutsche Bank has published a report on CVS Caremark CVS ahead of the company's Analyst Day, showing an expected EPS range on $3.15-$3.25.
In the report, Deutsche Bank writes, "CVS issued guidance for FY12, ahead of its Analyst Day presentation. The company expects EPS in the range of $3.15‐$3.25, and brackets the consensus and DBe of $3.20. Retail operating profits are expected
to be up by 7%‐9%, and pharmacy services (PBM) are expected to be up 11%‐15%. Free cash flow is expected to be in the range of $4.3‐$4.6 billion range. The guidance assumes completion of $3 billion in share repurchases, and does not contemplate any potential benefit from the ongoing dispute between ESRX and WAG."
Deutsche Bank maintains its Hold rating and $40 price target on CVS Caremark, which closed yesterday at $36.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in